Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where G Gambaccini is active.

Publication


Featured researches published by G Gambaccini.


Movement Disorders | 2001

Intravenous amantadine improves levadopa-induced dyskinesias: an acute double-blind placebo-controlled study.

Paolo Del Dotto; N Pavese; G Gambaccini; S Bernardini; Leonard Verhagen Metman; Thomas N. Chase; Ubaldo Bonuccelli

Experimental evidence suggests that glutamatergic receptor blockade may improve the motor response complications associated with long‐term levodopa treatment in Parkinsons disease (PD) patients. Our objective was to evaluate the acute effect of amantadine, a noncompetitive antagonist of the N‐methyl‐D‐aspartate (NMDA) receptor, on levodopa‐induced dyskinesias, and to gain further insights into the antidyskinetic mechanism of this drug. Nine PD patients with motor fluctuations and severely disabling peak of dose dyskinesias received their first morning levodopa dose, followed by a 2‐hour intravenous amantadine (200 mg) or placebo infusion, on two different days. Parkinsonian symptoms and dyskinesias were assessed every 15 minutes during the infusion and for 3 hours thereafter, while patients were taking their usual oral antiparkinsonian therapy, by means of Unified Parkinsons Disease Rating Scale (UPDRS, motor examination), tapping test, and a modified Abnormal Involuntary Movement Scale (AIMS). Intravenous amantadine acutely improved levodopa‐induced dyskinesias by 50%without any loss of the anti‐parkinsonian benefit from levodopa. This study confirms the antidyskinetic effect of amantadine and strengthens the rationale for using antiglutamatergic drugs in the treatment of parkinsonian motor fluctuations.


Neurology | 2002

Oxidative damage and cytogenetic analysis in leukocytes of Parkinson’s disease patients

L. Migliore; L. Petrozzi; Claudio Lucetti; G Gambaccini; S Bernardini; R. Scarpato; F. Trippi; R. Barale; G. Frenzilli; V. Rodilla; Ubaldo Bonuccelli

Background: Postmortem studies suggest excessive free radical toxicity in the substantia nigra of patients with PD. Increased lipid peroxidation and oxidative DNA damage have been reported in the CNS. Markers of oxidative stress have been identified in the blood of patients with PD. Objective: To assess the presence of spontaneous chromosome and primary or oxidative DNA damage in peripheral blood leukocytes of patients with untreated PD. Methods: Patients with de novo PD (20) and control subjects (16), matched for age, sex, and smoking habits, underwent cytogenetic analysis using the human lymphocyte micronucleus assay coupled with the fluorescence in situ hybridization technique and the Comet assay. Results: Compared with controls, patients with PD showed an increase in the incidence of spontaneous micronuclei (p < 0.001); single strand breaks (p < 0.001); and oxidized purine bases (p < 0.05). Fluorescence in situ hybridization analysis showed micronuclei harboring acentric fragments. Conclusions: There is chromosomal, primary DNA damage and oxidative DNA damage demonstrable in lymphocytes of patients with untreated PD.


Neurology | 2000

Paroxetine in Parkinson’s disease: Effects on motor and depressive symptoms

Roberto Ceravolo; Angelo Nuti; Armando Piccinni; Grazia Dell'Agnello; Giovanna Bellini; G Gambaccini; Liliana Dell'Osso; Luigi Murri; Ubaldo Bonuccelli

Article abstract Selective serotonin reuptake inhibitors have been used in the treatment of depression in patients with PD. Conflicting data as to whether selective serotonin reuptake inhibitors worsen parkinsonian motor symptomatology have been reported. In this study, the additional 6 months therapy with paroxetine 20 mg/d in a group of depressed patients with PD did not modify parkinsonian motor function (Unified Parkinson’s Disease Rating Scale scores); however, in one patient, fully reversible worsening of tremor was observed. Depression, as evaluated by Beck Depression Inventory and Hamilton Depression Rating Scale, improved from baseline to final visit (p < 0.05 by analysis of variance).


Neurological Sciences | 2002

Cytogenetic alterations in lymphocytes of Alzheimer's disease and Parkinson's disease patients

Lucia Petrozzi; Claudio Lucetti; Roberto Scarpato; G Gambaccini; F. Trippi; S Bernardini; P Del Dotto; Lucia Migliore; Ubaldo Bonuccelli

Abstract. We investigated the presence of cytogenetic alterations in peripheral blood lymphocytes of Alzheimers disease (AD) and Parkinsons disease (PD) patients. Detection of spontaneous structural and/or numerical chromosome damage has been assessed by micronucleus (MN) assay coupled with fluorescence in situ hybridization (FISH). The cytogenetic investigation was performed on 22 AD patients, 18 PD patients, and 20 controls. The spontaneous frequencies of micronuclei (MN) in human lymphocytes of both AD and PD patients were significantly higher than in controls. The majority of MN was composed of whole chromosomes in AD patients, while a prevalence of MN arising from chromosome breakage was observed in PD patients. Different molecular mechanisms underlie cytogenetic alterations observed in peripheral lymphocytes of AD and PD patients.


Movement Disorders | 1999

Acute and chronic effects of clozapine in essential tremor

Roberto Ceravolo; Stefania Salvetti; Paola Piccini; Claudio Lucetti; G Gambaccini; Ubaldo Bonuccelli

Patients with essential tremor (ET) may not respond to commonly used drugs. Clozapine, an atypical neuroleptic drug, has been reported to improve postural Parkinsons disease tremor clinically resembling ET. The effects of a single dose of 12.5 mg clozapine and placebo were evaluated in a randomized, double‐blind, crossover study in 15 drug‐resistant patients with ET. Patient responders with more than 50% improvement after a single dose of clozapine subsequently received the drug (39 ± 9 mg up to 50 mg) unblinded for a period of 15.8 ± 7.7 months. Tremor was effectively reduced by a single dose of clozapine in 13 of 15 patients (p <0.01). Sedation was the only side effect reported during the clozapine test; however, the time course of sedation and of the antitremor effect were not coincident. A significant reduction of tremor was reported with chronic clozapine treatment (p <0.01) with no tolerance to drug antitremor effect, whereas sedation markedly decreased after 6–7 weeks of therapy. No clozapine‐induced hematologic side effects were observed in our cohort of patients during long‐term treatment. Our results suggest that in selected drug‐resistant ET cases, clozapine should be considered before resorting to neurosurgical options.


Journal of Neural Transmission | 2004

Presynaptic nigro-striatal function in a group of Alzheimer's disease patients with parkinsonism: evidence from a dopamine transporter imaging study

Roberto Ceravolo; Duccio Volterrani; G Gambaccini; S. Bernardini; C Rossi; Chiara Logi; Gloria Tognoni; G Manca; Giuliano Mariani; Ubaldo Bonuccelli; Luigi Murri

Summary.The occurrence of parkinsonism in Alzheimer’s disease (AD) is quite common, however the molecular and neurochemical changes underlying such extrapyramidal features in AD have been not fully understood. Post-mortem as well as in vivo imaging study have produced conflicting results as regards the existence of dopaminergic changes in AD. Aim of the present study was to investigate in vivo the nigro-striatal dopaminergic function in a group of AD patients with parkinsonism. Thirteen patients with AD and extrapyramidal features not related to past neuroleptic use (AD-P) underwent SPECT with 123I-FP-CIT, a ligand of dopamine transporter, and the data were compared with those obtained in 15 patients with Diffuse Lewy Body Dementia (DLBD), 20 patients with Parkinson’s disease (PD), and 8 healthy elderly controls. The analysis of the data was performed by regions-of-interest approach and calculations of the striatal-to-non specific (occipital lobes) radioactivity ratios were made. The 123I-FP-CIT striatal uptake in patients with AD-P was similar to that obtained in the control population. Both the DLBD and PD groups showed significantly lower 123I-FP-CIT uptake in all striatal areas with respect to AD-P and control groups (p<0.005). The lack of dopamine transporter changes in our series of AD-P patients can indicate that dopaminergic presynaptic function is preserved in this population and that different dopaminergic changes such as postsynaptic ones, or different neurotransmitter alterations might underlie the extrapyramidal features in AD.


Neurological Sciences | 2001

Proton magnetic resonance spectroscopy (1H-MRS) of motor cortex and basal ganglia in de novo Parkinson's disease patients

Claudio Lucetti; P Del Dotto; G Gambaccini; S Bernardini; Mc Bianchi; Michela Tosetti; Ubaldo Bonuccelli

Abstract Proton MR spectroscopy (1H-MRS) has been previously performed in Parkinsons disease (PD) and parkinsonian syndromes to evaluate in vivo concentrations of basal ganglia and cerebral cortex metabolites such as N-acetylaspartate (NAA), choline (Cho), and creatine (Cr). However, this technique has never been used to evaluate motor cortex in untreated PD patients. In this study, single-voxel 1-H-MRS of basal ganglia and motor cortex was carried out in 10 de novo patients with PD and 10 age-matched healthy controls. A significant reduction in the NAA/Cr ratio was observed in the motor cortex of PD patients compared with controls (p<0.01). Basal ganglia spectra did not allow any evaluation due to the presence of artefacts related to inorganic paramagnetic substances. The motor cortex reduction of the NAA/Cr ratio in de novo PD patients may reflect an altered neuronal functioning due to a loss of thalamocortical excitatory inputs and may represent an in vivo marker for the diagnosis of PD.


Neurological Sciences | 2001

Cytogenetic analysis oxidative damage in lymphocytes of Parkinson's disease patients

Lucia Petrozzi; Claudio Lucetti; G Gambaccini; S Bernardini; P Del Dotto; Lucia Migliore; Roberto Scarpato; Ubaldo Bonuccelli

Abstract Several lines of evidence support the presence of DNA damage in somatic cells of Parkinsons disease (PD) patients due to the formation of free radical species. In order to detect spontaneous chromosome and primary or oxidative DNA damage, we performed the human lymphocyte micronucleus assay (HLMDA) and comet assay in 19 PD patients and 16 healthy controls. Compared with controls, PD patients showed a significant increase in: (1) spontaneous micronucleus (MN) frequency (p<0.001); (2) single strand break (SSB) levels (p<0.001); and (3) oxidized purine base levels (p<0.05). The chromosome damage and the increased levels of oxidized purine bases observed in our patients support the hypothesis of oxidative stress as a relevant factor in the pathogenesis of PD.


Italian Journal of Neurological Sciences | 1999

Clinical outcome and magnetic resonance imaging of carbon monoxide intoxication. A long-term follow-up study.

N Pavese; Alessandro Napolitano; G De Iaco; R. Canapicchi; Pl Collavoli; Claudio Lucetti; G Gambaccini; Ubaldo Bonuccelli

Abstract The clinical and neuroradiological outcome of carbon monoxide (CO) intoxication was evaluated prospectively in 30 patients over a follow-up period of 3 years. Among the patients studied, 22 had been acutely exposed to CO while 8 were chronically exposed.One month after CO poisoning, 12 of the 22 patients with acute intoxication showed magnetic resonance imaging (MRI) abnormalities: 6 also had neurological sequelae and 6 were asymptomatic. The remaining 10 patients showed neither MRI abnormalities nor neurological sequelae. During the 3-year follow-up, 4 of the patients with both MRI abnormalities and neurological sequelae improved in both clinical features and MRI findings. One of the 6 asymptomatic patients with MRI abnormalities developed a progressive cognitive impairment 2 months after acute intoxication, with a concomitant severe worsening of the MRI lesions. Among the 10 patients with neither MRI abnormalities nor neurological sequelae, only 1 developed neurological sequelae after a clear period of 4 months.In the group of patients who experienced chronic CO intoxication, only 1 presented with a neuropsychiatric syndrome which improved at follow-up. Brain MRI showed white matter lesions which remained unchanged at control scan after 1 year.In conclusion, we observed that some patients with severe CO poisoning and neurological sequelae may fully regain normal functions after approximately 1 year. The presence of MRI lesions 1 month after CO poisoning did not accurately predict the subsequent outcome. The observation of a clear period longer than the usual 2–40 day interval in 2 patients should be considered for careful planning of follow-up and for prognosis in CO-poisoned patients.


Neurological Sciences | 2003

Dopaminergic degeneration and perfusional impairment in Lewy body dementia and Alzheimer's disease

Roberto Ceravolo; Duccio Volterrani; G Gambaccini; C Rossi; Chiara Logi; G Manca; Caterina Berti; Giuliano Mariani; Luigi Murri; Ubaldo Bonuccelli

Abstract.The clinical differentiation of Lewy body dementia (LBD) from Alzheimer’s disease (AD) may be difficult. The aim of the present study was to assess the dopamine transporter function and the perfusional pattern in LBD and AD in vivo. Twenty patients with probable LBD and 24 with probable AD underwent on 2 separate days a brain perfusional SPECT with 99mTc-ECD and a SPECT with 123I-FP-CIT, a ligand of dopamine transporter. In LBD a significantly (p<0.0005) lower ratio of specific (bilateral caudate nucleus, putamen) to non-specific (occipital cortex) 123I-FP-CIT binding than in AD was reported. Perfusional data (SPM analysis) showed a significant (p<0.001) decrease of temporo-parietal blood flow in AD versus LBD, whereas in LBD a significant (p<0.001) occipital hypoperfusion with respect to AD was reported. Our findings confirm that dopaminergic nigrostriatal function is impaired in LBD. The selective occipital hypoperfusion in LBD needs to be further investigated.

Collaboration


Dive into the G Gambaccini's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Giuseppe Rossi

National Research Council

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge